AstraZeneca PLC (LON:AZN) Receives £145.83 Average PT from Analysts

Shares of AstraZeneca PLC (LON:AZN) have earned an average rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is £145.83.

Several brokerages have recently commented on AZN. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a report on Thursday, January 15th. Shore Capital Group restated a “buy” rating on shares of AstraZeneca in a research report on Friday, January 16th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of AstraZeneca from £105 to £110 and gave the stock a “sell” rating in a research note on Thursday, January 15th. Citigroup assumed coverage on shares of AstraZeneca in a research note on Tuesday, January 27th. They set a “buy” rating and a £170 price target on the stock. Finally, Berenberg Bank raised their price target on shares of AstraZeneca from £145 to £160 and gave the company a “buy” rating in a report on Tuesday, January 27th.

AstraZeneca Trading Up 2.6%

AZN stock opened at £154.98 on Friday. The business has a fifty day moving average price of £141.86 and a 200 day moving average price of £131.35. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. AstraZeneca has a fifty-two week low of GBX 9,573.51 and a fifty-two week high of £157.32. The stock has a market capitalization of £240.26 billion, a price-to-earnings ratio of 25.74, a P/E/G ratio of 0.86 and a beta of 0.17.

Insider Activity at AstraZeneca

In other news, insider Nazneen Rahman sold 297 shares of the business’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of £134.96, for a total transaction of £40,083.12. Company insiders own 0.15% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.